Abstract 129P
Background
Biliary tract cancers (BTC) are classified as gallbladder tumours (GBC) and intrahepatic (iCCA) or perihilar and distal extrahepatic cholangiocarcinomas (eCCA). BTC’s 3-year recurrence rate is up to 80%. Capecitabine (CAP) is the standard for adjuvant (adj) chemotherapy (CT). We collected a retrospective multicentre Italian series of resected BTC and analysed the impact of adj CT on survival.
Methods
Main variables were ECOG performance status (PS), pre-surgical (SUR) Ca 19.9 value, type of SUR, site, histology, invasion (T), nodal status (N), vascular invasion (V) resection margins (R), grade (G). Median follow-up (FU) was estimated with reverse Kaplan-Meier (KM) approach; median RFS (RFS) and median overall survival (OS) were estimated by KM method.
Results
We included 142 all-stages BTC resected from 2005 to 2022, adj CT was given to 69 BTC. With median FU of 89 months (mo), overall RFS and OS were 17 and 30 mo. Lower ECOG PS was associated with longer RFS and OS (p<0.001). A pre-SUR Ca19.9 ≤ 29 was associated with longer RFS in iCCA (p=0.001) and OS both in iCCA (p=0.010) and GBC (p=0.019). Lower T was associated with longer RFS (p=0.002) and OS (p<0.001) in iCCA and GBC but not in eCCA. N0 status correlated with longer RFS in iCCA (p<0.001) and OS both in iCCA and GBC (p<0.006). R0 status was associated with longer RFS in eCCA (p=0.043) and GBC (p<0.001), showing longer OS only in GBC only (p<0.001). V0 status was associated with longer RFS (p=0.017) and OS (p=0.009) in iCCA . Adj CT didn’t impact both on RFS (p=0.539) and OS (p=0.978) in the whole cohort. After stratification by site, eCCA showed an advantage given by adj CT on mRFS (p=0.047). Comparing all adj CT, CAP performed better in iCCA, with a mRFS of 19 mo. Multivariate Cox regression analysis for RFS and OS was stratified for iCCA, eCCA and GBC: ECOG PS, R and N status retained significant correlation with RFS (p<0.001, p<0.001 and p=0.034, respectively) and OS (p<0.001, p<0.001, p=0.013, respectively). Pre-SUR Ca19.9 value correlated with OS (p=0.001).
Conclusions
In our series, adj CT didn’t impact on survival except for eCCA. Evaluation of multiple prognostic variables (including T, N, R and V status and pre-SUR Ca19.9) is necessary to identify a subgroup of BTC that can benefit more from adj CT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
107P - Comprehensive genomic profiling of “The German-registry of incidental gallbladder carcinoma” cases
Presenter: Nihat Bugra Agaoglu
Session: Poster session 17
108P - FGFR2 fusions and their impact on efficacy of standard chemotherapy in patients with biliary tract cancer
Presenter: Binbin Zheng-Lin
Session: Poster session 17
109P - DNA damage repair pathways in biliary tract cancer: A new target for precision medicine?
Presenter: Ilektra Mavroeidi
Session: Poster session 17
110P - Detection of HER2 overexpression in biliary tract cancers: Comparison of AmoyDx® HER-2 (29D8) assay with ventana PATHWAY anti-HER-2/neu (4B5) assay
Presenter: Hui Dong
Session: Poster session 17
111P - The concordance between circulating tumor DNA and tissue genomic profiling in patients with advanced biliary tract cancer
Presenter: Seonjeong Woo
Session: Poster session 17
112P - Clinical, genomic and transcriptomic characteristics of young-onset biliary tract cancers
Presenter: Thomas Pudlarz
Session: Poster session 17
113P - Molecular profiling of biliary tract cancers in patients of African and European ancestries
Presenter: Zishuo Hu
Session: Poster session 17
114P - Prospective longitudinal tumor-informed ctDNA in resectable biliary tract cancers
Presenter: Gentry King
Session: Poster session 17
115P - Inhibition of KLF5 reduces tumor growth and sensitizes to chemotherapy-induced cell death in experimental models of cholangiocarcinoma
Presenter: Ana Landa Magdalena
Session: Poster session 17